The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Using CRISPR to identify the next generation of CAR T-cell targets
Sandrine Roulland, PharmD, PhD, Center for Immunology of Marseille-Luminy (CIML), Marseille, France, explores how CRISPR screening is being used to identify new targets that could improve CAR T-cell therapies. She discusses the shift from in vitro to in vivo models, the potential to enhance T-cell expansion and tumour infiltration, and the challenges that remain before these discoveries can be translated into clinical practice. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
